Renalytix (
RENX · AIM · Health Care · mcap £36m · 5.3p
| Date | Type | Announcement | Day |
|---|---|---|---|
| 05 Oct 26 | Holding | Holding(s) in Company | |
| 02 Oct 26 | Director dealing | Director/PDMR Shareholding (Replacement) | |
| 02 Oct 26 | Holding | Holding(s) in Company | |
| 01 Oct 26 | Holding | Holding(s) in Company | |
| 01 Oct 26 | Director dealing | Director/PDMR Shareholding | |
| 01 Oct 26 | Holding | Holding(s) in Company | |
| 30 Sep 26 | Holding | Holding(s) in Company | |
| 28 Sep 26 | Result of General Meeting
LONDON and NEW YORK, 28 September 2026 – Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company focused on kidney disease, announces that at the General Meeting (“GM”) held earlier today, all |
+0.0% | |
| 28 Sep 26 | Board change | Directorate Change
Non-Executive Chair Julian Baines to step down on 31 December 2026; company seeking replacement. |
+0.0% |
| 25 Sep 26 | Investor Presentations
LONDON and NEW YORK, 25 September 2026 – Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company focused on kidney disease, announces that it will host a live online investor presentation next |
+0.0% | |
| 16 Sep 26 | Holding | Holding(s) in Company | |
| 16 Sep 26 | Holding | Holding(s) in Company | |
| 16 Sep 26 | Board change | Additional CEO Share Purchase
CEO James McCullough purchased 500 ADS (25,000 Ordinary Shares) at average price $4.30. |
+5.0% |
| 14 Sep 26 | Holding | Holding(s) in Company | |
| 14 Sep 26 | New Accounting Ref Date
Accounting reference date changed from 30 June to 31 December, with 18-month transition period to 31 December 2026. |
+1.6% | |
| 11 Sep 26 | Holding | Holding(s) in Company | |
| 11 Sep 26 | Holding | Holding(s) in Company | |
| 11 Sep 26 | Board change | CEO Share Purchase
CEO James McCullough purchased 340 ADS at average price of US$3.875 per ADS on 8-9 September 2026. |
+12.5% |
| 10 Sep 26 | Holding | Holding(s) in Company | |
| 09 Sep 26 | Holding | Holding(s) in Company | |
| 09 Sep 26 | Holding | Holding(s) in Company | |
| 08 Sep 26 | Routine | Posting of Circular and Notice of AGM | |
| 08 Sep 26 | Holding | Holding(s) in Company | |
| 08 Sep 26 | Holding | Holding(s) in Company | |
| 08 Sep 26 | Capital Access Window - Renalytix Plc | +30.1% | |
| 08 Sep 26 | Fundraise | Result of WRAP Retail Offer
Renalytix completed £380,142 retail offer at 6p per share, raising £10.5m gross in total fundraise. |
+30.1% |
| 04 Sep 26 | Holding | Holding(s) in Company | |
| 03 Sep 26 | Offer | WRAP Retail Offer for up to £1,000,000
Renalytix raises up to £1m via retail offer at 6p per share, following £10.1m placing and convertible bond conversion. |
+0.0% |
| 03 Sep 26 | Fundraise | Result of Fundraise
Renalytix raised £10.1m gross via placing of 168.4m shares at 6p, with Heights Capital converting £13.6m debt to equity. |
+0.0% |
| 02 Sep 26 | Holding | Holding(s) in Company | |
| 01 Sep 26 | Holding | Holding(s) in Company | |
| 01 Sep 26 | Capital Access Window - Renalytix plc | +0.0% | |
| 01 Sep 26 | Fundraise | Proposed Fundraise
Renalytix raises approximately £9.5 million at 6 pence per share to support strategic collaboration. |
+0.0% |
| 01 Sep 26 | Collaboration with Quest Diagnostics
Renalytix signs multi-year agreement with Quest Diagnostics to expand kidneyintelX.dkd testing across US. |
+0.0% | |
| 24 Aug 26 | AIM Rule 17 Disclosure
Non-Executive Director Erik Lium was director of Trellus Health plc before it entered administration on 24 August 2026. |
+10.4% | |
| 10 Aug 26 | Holding | Holding(s) in Company | |
| 29 Jul 26 | Holding | Holding(s) in Company | |
| 27 Jul 26 | Holding | Holding(s) in Company | |
| 07 Jul 26 | Holding | Holding(s) in Company | |
| 30 Jun 26 | Real world evidence study data published
Two-year real-world evidence study published showing kidneyintelX.dkd test improves kidney function and increases guideline-directed therapy uptake. |
+21.1% | |
| 29 May 26 | Holding | Holding(s) in Company | |
| 27 May 26 | Holding | Holding(s) in Company | |
| 18 May 26 | Holding | Holding(s) in Company | |
| 05 May 26 | Holding | Holding(s) in Company | |
| 05 May 26 | Holding | Holding(s) in Company | |
| 01 May 26 | Holding | Holding(s) in Company | |
| 29 Apr 26 | Holding | Holding(s) in Company | |
| 23 Apr 26 | Holding | Holding(s) in Company | |
| 23 Apr 26 | Holding | Holding(s) in Company | |
| 22 Apr 26 | Key milestones achieved for kidneyintelX.dkd
New laboratory enables 3.5x capacity increase; CE marking submission completed for kidneyintelX.dkd. |
+0.0% | |
| 16 Apr 26 | Holding | Holding(s) in Company | |
| 16 Apr 26 | Holding | Holding(s) in Company | |
| 09 Apr 26 | Holding | Holding(s) in Company | |
| 07 Apr 26 | Holding | Holding(s) in Company | |
| 07 Apr 26 | Holding | Holding(s) in Company | |
| 30 Mar 26 | Holding | Holding(s) in Company | |
| 26 Mar 26 | Results | Half-year Results
H1 26 revenue $1.6m, up 23% YoY; 58 new practice sites added; FY26 revenue guidance set at c.$4m. |
+6.8% |
| 18 Mar 26 | Holding | Holding(s) in Company | |
| 17 Mar 26 | Holding | Holding(s) in Company | |
| 13 Mar 26 | Holding | Holding(s) in Company | |
| 27 Feb 26 | Holding | Holding(s) in Company | |
| 13 Feb 26 | Board change | Further CEO Share Purchase
CEO James McCullough purchased 750 ADS at average price of US$3.15 per ADS. |
+1.9% |
| 13 Feb 26 | Director dealing | Director/PDMR Shareholding | |
| 12 Feb 26 | Director dealing | Director/PDMR Share Purchase
LONDON and NEW YORK, 12 February 2026 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, whose product kidneyintelX.dkd, is the only FDA-approved and Medicare-reimbursed prognostic test |
−1.8% |
| 12 Feb 26 | Board change | CEO Share Purchase
CEO James McCullough purchased 3,010 ADS at average price of US$3.01 per ADS on 11 February 2026. |
−1.8% |
| 11 Feb 26 | Trading update | H1 Trading update
H1 FY26 revenues $1.6m; FY26 guidance $4m (up 33% YoY); three new healthcare integrations completed. |
−26.3% |
| 21 Jan 26 | Holding | Holding(s) in Company | |
| 15 Jan 26 | Holding | Holding(s) in Company | |
| 12 Jan 26 | Three kidneyintelX.dkd Clinical Integrations
Completed three clinical integrations for kidneyintelX.dkd test; testing volumes commenced across all sites. |
+0.0% | |
| 09 Jan 26 | Holding | Holding(s) in Company | |
| 06 Jan 26 | Holding | Holding(s) in Company | |
| 24 Dec 25 | Holding | Holding(s) in Company | |
| 23 Dec 25 | Holding | Holding(s) in Company | |
| 19 Dec 25 | Holding | Holding(s) in Company | |
| 17 Dec 25 | Holding | Holding(s) in Company | |
| 16 Dec 25 | Holding | Holding(s) in Company | |
| 09 Dec 25 | Routine | Result of AGM | |
| 09 Dec 25 | AGM Statement
LONDON and NEW YORK, 9 December 2025 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, with kidneyintelX.dkd, the only FDA-approved and Medicare reimbursed prognostic test to support e |
−7.4% | |
| 27 Nov 25 | Holding | Holding(s) in Company | |
| 25 Nov 25 | Holding | Holding(s) in Company | |
| 25 Nov 25 | Plan to Implement ADS Ratio Change
Renalytix to implement 1-for-25 reverse ADS split, effective 12 December 2025. |
+0.0% | |
| 12 Nov 25 | Pivotal kidneyintelX.dkd data published
kidneyintelX.dkd pivotal trial data published in Diabetes Care; three abstracts presented at ASN Kidney Week. |
−5.5% | |
| 05 Nov 25 | Holding | Holding(s) in Company | |
| 04 Nov 25 | Routine | Publication of Annual Report & Notice of AGM | |
| 03 Nov 25 | Holding | Holding(s) in Company | |
| 03 Nov 25 | Results | Audited Full Year Fiscal 2025 Results
FY25 revenues up 30% to $3.0m, testing volumes up 37%, underlying EBITDA loss down 54%. |
−10.5% |
| 30 Oct 25 | Holding | Holding(s) in Company | |
| 28 Oct 25 | Holding | Holding(s) in Company | |
| 27 Oct 25 | Confirmation of receipt of £860k R&D tax credits
Renalytix received £860k in R&D tax credits for fiscal years 2023 and 2024. |
+1.4% | |
| 24 Oct 25 | Holding | Holding(s) in Company | |
| 23 Oct 25 | Holding | Holding(s) in Company | |
| 21 Oct 25 | Holding | Holding(s) in Company | |
| 17 Oct 25 | Holding | Holding(s) in Company | |
| 17 Oct 25 | Holding | Holding(s) in Company | |
| 16 Oct 25 | Holding | Holding(s) in Company | |
| 16 Oct 25 | Holding | Holding(s) in Company | |
| 15 Oct 25 | Holding | Holding(s) in Company | |
| 10 Oct 25 | Holding | Holding(s) in Company | |
| 10 Oct 25 | Holding | Holding(s) in Company | |
| 10 Oct 25 | Holding | Holding(s) in Company | |
| 10 Oct 25 | $4m balance sheet improvement with bond conversion
Heights Capital converts $4m convertible bonds into 31.6m shares at 9.5p, improving balance sheet by $4m. |
+2.8% | |
| 09 Oct 25 | Holding | Holding(s) in Company | |
| 07 Oct 25 | Holding | Holding(s) in Company |
Company filings. Not investment advice.